Biotech Giant Amgen Misses Street’s Expectations
Comments (0) 
Amgen (AMGN), the world's largest biotechnology company, reported fourth-quarter results that missed Wall Street's expectations, as a 2% increase in sales failed to translate into a stronger bottom line. The quarter was a somewhat expected disappointment, as its adjusted earnings per share decreased 1% to $1.05 per share, below analyst estimates of $1.16 per share, according to Thomson Reuters.
Continue reading Biotech Giant Amgen Misses Street's Expectations
Biotech Giant Amgen Misses Street's Expectations originally appeared on DailyFinance on Mon, 25 Jan 2010 18:45:00.
Filed Under: Earnings, Amgen
